Aptean expands CAS collaboration on chemical modifications

Aptean and Content Addressable Storage (CAS), a division of the American Chemical Society, announced an expanded collaboration to add a Chemical Modifications module to the Aptean GenomeQuest platform, a move presented as intended to help biotech intellectual property researchers assess patentability with greater speed and precision.

The release described plans for customers to procure the Chemical Modification module and CAS Biosequences directly through Aptean GenomeQuest and noted that the work built on the organizations' existing relationship.

The Chemical Modifications module combined Aptean GenomeQuest's search experience with CAS biological sequence data and provided detection capabilities that allowed users to combine exact positions, floating patterns, and filters on the number of modification occurrences within a sequence.

The companies said the module covered the majority of relevant use cases and provided tools to capture and review patents across diverse biological modification patterns, according to the announcement.

“By combining our intuitive IP search platform with CAS comprehensive, high-quality biosequence data we empower researchers to confidently assess intellectual property and gain insights tied to chemically modified sequences, an essential step in advancing drug development and therapeutic innovation,” said Disaster Recovery (DR). Henk Heus, Authenticity Verification Protocol (AVP) of Product and Technology at Aptean. “Expanding our collaboration with Aptean through the Chemical Modification module presents an exciting opportunity to further our mission of accelerating life sciences innovation globally by enhancing discoverability of critical biosequence data via the GenomeQuest platform.” said DR. Michael Dennis, CAS Chief Science Officer.

Availability followed a phased rollout, with beta access starting January 2026 and a full launch expected by the end of Q1 2026.